News

Leading ovarian cancer organization announces 2017 honorees

Leading ovarian cancer organization announces 2017 honorees

July 26, 2017

Largest private funder of ovarian cancer research recognizes top researchers and community leaders NEW YORK — Today, Ovarian Cancer Research Alliance (OCRFA), the nation’s leading ovarian cancer research, advocacy and patient support organization, announces this year’s winners of its research and survivor awards at its annual conference. OCRFA honors two outstanding researchers for their cutting-edge … Continued

OCRA News

USPSTF Does Not Recommend Ovarian Cancer Screening for Gene...

USPSTF Does Not Recommend Ovarian Cancer Screening for General Population

July 19, 2017

(July 19, 2017) The United States Preventative Services Task Force (USPSTF) has once again recommended against screening for ovarian cancer in asymptomatic, average risk women. The draft statement, which was published on July 18th, does not apply to women who are positive for BRCA1 and BRCA2 genetic mutations, who have a higher risk of developing … Continued

Research

OCRFA Earns 4-Star Rating from Charity Navigator

OCRFA Earns 4-Star Rating from Charity Navigator

July 6, 2017

(July 6, 2017) OCRFA is pleased to announce we have once again earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This rating, the highest awarded by Charity Navigator, demonstrates OCRFA’s continued commitment to maintaining responsible fiscal management practices, as well as transparency and accountability, as we continue to strive toward a cure for ovarian … Continued

OCRA News

Clinical Trial Shows Rucaparib Significantly Improved Progr...

Clinical Trial Shows Rucaparib Significantly Improved Progression-Free Survival in Ovarian Cancer Patients

July 6, 2017

(July 6, 2017) Clovis Oncology, Inc. recently announced topline data from the confirmatory phase 3 ARIEL3 trial of the drug rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied. Read the press release from Clovis Oncology.

Research

Age-Specific Risk in Women with BRCA1 and BRCA2 Mutations

Age-Specific Risk in Women with BRCA1 and BRCA2 Mutations

June 30, 2017

(June 30, 2017) Ten thousand women, most of whom are BRCA1 or BRCA2 positive, were analyzed by the University of Cambridge in order to find age specific risk for breast and ovarian cancers. The goal of the study, which was published in the Journal of the American Medical Association (JAMA), was to better enable clinicians … Continued

Research

Study Focused on Neuropathy in Female Cancer Survivors

Study Focused on Neuropathy in Female Cancer Survivors

June 23, 2017

(June 23, 2017) A clinical trial published in the Journal of Clinical Oncology focused on a largely understudied area of cancer survivorship: chemotherapy-induced peripheral neuropathy (CIPN) in women. Forty seven percent of the 512 women in the trial reported CIPN an average of 6 years after their treatment ended. Symptoms of CIPN reported during the … Continued

Research

Dept. of Health and Human Services Seeks to Limit Access to...

Dept. of Health and Human Services Seeks to Limit Access to Oral Contraception Benefits

June 6, 2017

According to recent reports, the Department of Health and Human Services (HHS) will soon seek to limit access to oral contraception benefits. “The proposed rule allowing employers to deny insurance coverage for birth control limits the application of oral contraceptives in preventive medicine, in particular, for ovarian cancer. Oral contraceptives have been shown to reduce … Continued

Advocacy

An Analysis on the Quality of Life in Long Term Survivors o...

An Analysis on the Quality of Life in Long Term Survivors of Advanced Stage Ovarian Cancer

June 1, 2017

(June 1, 2017) A study, published last month in Gynecologic Oncology, focused on an area of ovarian cancer that is rarely talked about: the quality of life (QOL) for long term survivors of advanced stage ovarian cancer. Woman surviving 8.5 years or longer, who had anywhere from 0 recurrences to multiple recurrences, were given surveys … Continued

Community

Action Alert: Protect Federal Funding for Ovarian Cancer Re...

Action Alert: Protect Federal Funding for Ovarian Cancer Research

May 27, 2017

The White House has released a proposed budget for FY2018 that makes drastic cuts to the budgets for the National Institute of Health (NIH) and Centers for Disease Control and Prevention (CDC). These cuts would reduce the NIH budget by 20% and threaten to halt breakthrough medical research advancements and delay life-saving cures. The proposed … Continued

Advocacy

The Risk of Blood Clots and Ovarian Cancer

The Risk of Blood Clots and Ovarian Cancer

May 25, 2017

(May 25, 2017) A retrospective study, published earlier this month in Obstetrics & Gynecology, looked at when women with ovarian cancer developed blood clots. One in four women diagnosed with ovarian cancer develop a blood clot, but more specifically, over eleven percent of those who developed a blood clot did so during neoadjuvant chemotherapy. Women … Continued

Research

The Positive Impact of Cognitive Behavior Therapy on Fear o...

The Positive Impact of Cognitive Behavior Therapy on Fear of Cancer Recurrence

May 22, 2017

(May 22, 2017) A recent study from the Netherlands found that a combination of cognitive behavior therapies had a positive effect on FCR, or Fear of Cancer Recurrence. Eighty-eight cancer survivors, including breast, prostate, and colorectal cancers, were divided into either a control group, which received usual care, or the therapy group. The participants that received … Continued

Research

OCRFA Funded Study Determines the Importance of Tumor Antigen

OCRFA Funded Study Determines the Importance of Tumor Antigen

May 2, 2017

(May 2, 2017) A study, published in Gynecologic Oncology, revealed the importance of tumor antigen NY-ESO-1 for ovarian cancer patients. This tumor antigen, although not normally found in healthy cells, is very prevalent in tumors such as epithelial ovarian cancers. Over the course of the 14 year study, Roswell Park tested 1,000 ovarian cancer patients … Continued

OCRA News